Budget’s funding welcome, but more is needed for pharmacy

PSA has welcomed the government’s commitment to pharmacy in the 2019-20 Federal Budget through the extension of the Administration Handling and Infrastructure (AHI) fee...

Pregabalin add-on for drug-resistant focal epilepsy

This evidence summary presents the best available evidence regarding pregabalin add-on for drug-resistant focal epilepsy.1 Introduction Approximately 3–3.5% of Australians will experience epilepsy at some point...

PSA NT/SA Branch’s vaccine advocacy work

The PSA SA/NT Branch is fighting for pharmacists to be able to administer more vaccines. Read more about it here.

Blockchain exec pushing for the end of paper prescriptions

Australian laws requiring use of paper documents prevent new technological solutions that could inhibit prescription fraud. That’s the diagnosis of Dr Tal Rapke, chief executive...

How should chronic pain in children be approached?

There is limited research on the effectiveness of pharmacotherapy in treating in children with chronic pain. So what is the best approach and how...

Listings for biosimilar uptake drivers expanded

Amended prescribing information has been released for two biosimilar uptake drivers listed on the Pharmaceutical Benefits Scheme (PBS), as part of the Biosimilar Awareness...